Phase III international, randomized study of Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin plus PLD in patients with ovarian cancer progressing within 6-12 months of last platinum
Trial Number
NCT01379989 (ClinicalTrials.gov Identifier)Contact Person
Status
Completed
Disease Site
Recurrent Ovarian
Lead Cooperative Group
Participating Groups
GEICO
SAKK
BGOG
DGOG
NOGGO
NSGO-CTU
AGO-AUST